ERBB2 and breast cancer: The use of trastuzumab deruxtecan in the treatment of HER2+ breast cancer is a successful example in which the BsAb binds to HER2/CD63 or HER2/PRLR and concurrently facilitates the internalization and lysosomal degradation essential for the action of the cytotoxic payload [18,19].